Animal parasiticides market was valued at $12.9 billion in 2025 and is projected to reach $26.4 billion by 2035, growing at a CAGR of 7.5% during the forecast Period (2026-2035). Expanding regulatory approvals for advanced parasiticides are boosting global availability and adoption, thereby significantly driving market growth in both developed and emerging economies. This trend is exemplified by recent approvals of long-acting injectable and multi-target parasiticides, which provide enhanced convenience and broader parasite control for companion animals. For instance, in July 2025, the FDA approved BRAVECTO QUANTUM (fluralaner for extended-release injectable suspension), a once-yearly injectable for treating and preventing flea and tick infestations in dogs. It will be available at veterinary clinics by August 2025. Previously approved in Australia, New Zealand, and the EU, it is now sanctioned in over 50 countries. BRAVECTO QUANTUM effectively kills adult fleas and controls various tick species for up to 12 months, with an 8-month treatment for lone star ticks, making it the first parasiticide with a full year of protection from a single dose.
Browse the full report description of “Animal Parasiticides Market Size, Share & Trends Analysis by Product Type (Endectocides, Ectoparasiticides, and Endoparasiticides), By Animal Type (Companion Animals, and Livestock), By Formulation (Oral, Topical, and Injectable), By Distribution Channel (Veterinary Hospitals & Clinics, Retail Pharmacies, Online Stores, and Others), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/animal-parasiticides-market
Recent Regulatory Approvals and Emergency Authorizations in the Animal Parasiticides Market
- In November 2025, a single-use injectable parasiticide, Bravecto Quantum, received approval from the US Food and Drug Administration, providing dogs with 12 months of protection against fleas and ticks. The product is now available to clinicians in the US, following its approval in over 50 countries, including Australia, New Zealand, and the European Union, since its initial introduction.
- In August 2025, HHS authorized the FDA to issue Emergency Use Authorizations for animal drugs against the New World Screwworm (NWS), which poses a threat to livestock and the US food supply. While the risk to humans is minimal, NWS can severely impact animal populations. Following its re-emergence in North America since 2022, the EUA will facilitate quicker access to alternative animal drug products to protect pets, livestock, and food security, as no FDA-approved medications for NWS are currently available in the US.
- In August 2025, HHS authorized the FDA to issue Emergency Use Authorizations for animal drugs against the New World Screwworm (NWS), which poses a threat to livestock and the U.S. food supply. While the risk to humans is minimal, NWS can severely impact animal populations. Following its re-emergence in North America since 2022, the EUA will facilitate quicker access to alternative animal drug products to protect pets, livestock, and food security, as no FDA-approved medications for NWS are currently available in the US.
- In April 2025, Zoetis' Simparica Trio gained FDA approval as the first canine parasiticide that prevents flea tapeworm infections by targeting vector fleas. It is the only product that combines protection against flea tapeworms, ticks, heartworms, and intestinal worms in a single monthly chewable tablet. Having been prescribed to over 15 million dogs, it effectively prevents Dipylidium caninum infections. Caution is recommended for dogs with a seizure history due to possible neurologic reactions, and its safety for breeding, pregnant, or lactating dogs is unverified.
Market Coverage
- The market number available for – 2025-2035
- Base year- 2025
- Forecast period- 2026-2035
- Segment Covered-
- By Product Type
- By Animal Type
- BY Formulation
- By Distribution Channel
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape - Boehringer Ingelheim International GmbH, Elanco Animal Health Inc., Merck & Co., Inc.,Virbac, Zoetis Inc.
Key questions addressed by the report.
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Animal Parasiticides Market Report Segment
By Product Type
- Endectocides
- Ectoparasiticides
- Endoparasiticides
By Animal Type
- Companion Animals
- Livestock
- Cattle
- Sheep
- Goats
- Pigs
- Poultry
By Formulation
- Oral
- Topical
- Injectable
- By Category
By Distribution Channel
- Veterinary Hospitals & Clinics
- Retail Pharmacies
- Online Stores
- Others (Feedlots, Direct Farm Sales)
Global Animal Parasiticides Market Report Segment by Region
North America
Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia and New Zealand
- ASEAN Economies
- Rest of Asia-Pacific
Rest of the World
- Latin America
- Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/animal-parasiticides-market